Get the Stockscreener App
2.41
0.00%
0.00
Oramed Pharmaceuticals Inc stock is traded at $2.41, with a volume of 234.
It is up +0.00% in the last 24 hours and up +0.00% over the past month.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
See More
Previous Close:
$2.41
Open:
$2.44
24h Volume:
234
Relative Volume:
0.00
Market Cap:
$100.05M
Revenue:
$2.70M
Net Income/Loss:
$5.53M
P/E Ratio:
21.91
EPS:
0.11
Net Cash Flow:
$-10.55M
1W Performance:
-1.63%
1M Performance:
+0.00%
6M Performance:
+14.22%
1Y Performance:
+1.26%
1-Day Range:
$2.44
$2.44
1-Week Range:
$2.31
$2.50
52-Week Range:
$1.82
$3.09
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Name
Oramed Pharmaceuticals Inc
Sector
Industry
Phone
646-844-1164
Address
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Compare ORMP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
2.44 | 98.82M | 2.70M | 5.53M | -10.55M | 0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.50 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.52 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
543.83 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
795.93 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-20-21 | Initiated | Canaccord Genuity | Buy |
| Feb-09-21 | Initiated | National Securities | Buy |
| Dec-03-20 | Initiated | Alliance Global Partners | Buy |
| Mar-11-20 | Initiated | Aegis Capital | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-17 | Resumed | B. Riley FBR, Inc. | Buy |
| May-26-16 | Reiterated | FBR Capital | Outperform |
| Dec-01-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-19-15 | Initiated | FBR Capital | Outperform |
| Apr-13-15 | Resumed | MLV & Co | Buy |
| Jan-30-14 | Reiterated | Aegis Capital | Buy |
| Jan-08-14 | Reiterated | Aegis Capital | Buy |
| Jan-08-14 | Initiated | MLV & Co | Buy |
| Dec-03-13 | Initiated | Aegis Capital | Buy |
View All
Oramed Pharmaceuticals Inc Stock (ORMP) Latest News
Visualizing Oramed Pharmaceuticals Inc. stock with heatmapsBreakout Watch & Real-Time Chart Pattern Alerts - newser.com
Exit strategy if you’re trapped in Oramed Pharmaceuticals Inc.2025 EndofYear Setup & Verified Trade Idea Suggestions - newser.com
Will Oramed Pharmaceuticals Inc. stock outperform Dow Jones index2025 Biggest Moves & Free Safe Capital Growth Stock Tips - newser.com
Oramed Pharmaceuticals Forms Golden Cross, Signaling Bullish Breakout Ahead - Markets Mojo
Oramed Pharmaceuticals Inc. stock outlook for YEARStop Loss & Expert Verified Movement Alerts - newser.com
Will Oramed Pharmaceuticals Inc. stock go up soonJuly 2025 Snapshot & Smart Allocation Stock Tips - newser.com
What’s the recovery path for long term holders of Oramed Pharmaceuticals Inc.2025 Technical Overview & Real-Time Buy Signal Alerts - newser.com
Weiss Ratings Reaffirms Sell (D) Rating for Oramed Pharmaceuticals (NASDAQ:ORMP) - MarketBeat
Analyzing recovery setups for Oramed Pharmaceuticals Inc. investorsGold Moves & Free AI Powered Buy and Sell Recommendations - newser.com
How to track smart money flows in Oramed Pharmaceuticals Inc.July 2025 Pullbacks & Weekly Market Pulse Updates - newser.com
Is Oramed Pharmaceuticals Inc. stock affected by interest rate hikesWeekly Trade Summary & AI Optimized Trading Strategy Guides - newser.com
How supply chain issues affect Oramed Pharmaceuticals Inc. stockJuly 2025 Levels & Low Drawdown Momentum Ideas - newser.com
Is Oramed Pharmaceuticals Inc OJU1 a good long term investmentPrice Volatility Patterns & Free Double Digit Growth Tips - earlytimes.in
What analysts say about Oramed Pharmaceuticals Inc stockEarnings Season Recap & Small Budget Wealth Building - earlytimes.in
Oramed Pharmaceuticals completes first tranche of Scilex warrant repurchase - Investing.com
Oramed Pharm Completes Warrant Repurchase Agreement - TipRanks
How to forecast Oramed Pharmaceuticals Inc. trends using time seriesQuarterly Earnings Summary & Community Supported Trade Ideas - newser.com
What MACD signals say about Oramed Pharmaceuticals Inc.Weekly Trade Recap & Intraday High Probability Alerts - newser.com
Can Oramed Pharmaceuticals Inc. (OJU1) stock withstand sector downturnsSell Signal & Safe Entry Point Identification - newser.com
Can Oramed Pharmaceuticals Inc. stock attract ESG capital inflowsEarnings Risk Report & Free Community Supported Trade Ideas - newser.com
What institutional flow reveals about Oramed Pharmaceuticals Inc.2025 Market Overview & Free Accurate Trade Setup Notifications - newser.com
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Short Interest Down 35.7% in September - MarketBeat
Will Oramed Pharmaceuticals Inc. bounce back from current supportWeekly Volume Report & Verified Stock Trade Ideas - newser.com
Can Oramed Pharmaceuticals Inc. stock deliver surprise earnings beatMarket Movers & Fast Exit Strategy with Risk Control - newser.com
Has Oramed Pharmaceuticals Inc. found a price floorJuly 2025 Pullbacks & Real-Time Chart Pattern Alerts - newser.com
Analyzing net buyer seller activity in Oramed Pharmaceuticals Inc.Buy Signal & Technical Pattern Based Signals - newser.com
Using RSI to spot recovery in Oramed Pharmaceuticals Inc.2025 Short Interest & Real-Time Volume Triggers - newser.com
Will Oramed Pharmaceuticals Inc. stock see PE expansionTrade Analysis Summary & Daily Profit Maximizing Tips - newser.com
Oramed Pharmaceuticals Inc Stock (ORMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.81%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):